glp-1 drugs and breast cancer Study shows tiny difference in women on GLP‑1 Breast cancer: GLP-1 use may

Similar content being viewed by others Introduction Type 2 diabetes mellitus (T2DM) is a prevalent disease with the potential to become a pandemic and one of the leading causes of mortality worldwide [1, 2]

Abdominal fat loss, as well as sustained reductions of fasting insulin levels and markers of IR, have been also shown to individuals with overweight/obesity, prediabetes, PCOS and OSA during their administration [31, 38, 6770]

The key periconception safety boundaries remain explicit contraception during treatment, drug-specific discontinuation, and completion of the recommended washout period before conception attempts

However, several researchers are currently developing oral GLP-1 agonists for treating type 2 diabetes and obesity

Most probably, the observation period of six months was too short to sensitively detect worsening in visual outcomes, including GCL volume loss, also proven by a recent study in which a delayed decline in visual field and GCL volume after 12 months was seen [39]